Rising antifolate resistance weakens the case for sulfadoxine-pyrimethamine
Ugandan children with sickle cell anaemia receiving malaria chemoprevention were carrying parasites already armed with a dense cluster of antifolate resistance markers, a molecular pattern that narrows the usefulness of monthly sulfadoxine-pyrimethamine (SP). The nested analysis inside the CHEMCHA randomised trial found that the dominant parasite background was the quintuple mutant Pfdhfr IRN/Pfdhps GE, a genotype long associated with high-grade SP resistance across East Africa.
The finding is hard to ignore in a population where malaria prevention carries extra weight. Children with sickle cell anaemia face a higher burden from malaria infection, and any chemoprevention strategy must work in a setting where parasite pressure and drug resistance are both intense. In that context, a regimen built on SP has to overcome pre-existing antifolate selection, and this study suggests the parasite population has already moved far beyond that threshold.
Molecular surveillance at baseline and endline showed entrenched resistance
This prospective substudy drew on dried blood spots collected at enrolment, study closeout, and during febrile episodes from children aged 6 months to 15 years attending Jinja and Kitgum hospitals. Parasite DNA from microscopy-confirmed malaria samples underwent amplicon sequencing for Pfdhfr and Pfdhps mutations, while complexity of infection was estimated with MOIRE. Complete haplotypes were resolved for 7 to 28 isolates per site and time point, and complexity of infection was estimated in 67 samples.
Across those samples, the quintuple mutant remained the overwhelming pattern, accounting for 85.7% to 100% of isolates across sites and time points. A613S and A613T were not detected. In a region where SP has been widely used, that distribution signals a parasite population under sustained antifolate selection rather than a transient pocket of resistance. The biology is straightforward: mutations in dhfr and dhps impair the binding of pyrimethamine and sulfadoxine to their targets in folate synthesis, reducing the drug combination’s ability to interrupt parasite replication.
A single sentence captures the practical consequence. The parasite pool was already dominated by resistance before new infections were even counted.
Higher-level resistance markers appeared during follow-up
The study also picked up markers that raise the resistance ceiling further. Pfdhfr I164L appeared in 2 of 9 isolates in Jinja at baseline and 1 of 8 at endline. Pfdhps A581G, absent at baseline in 0 of 44 isolates, emerged later in 1 of 8 isolates in Jinja and 3 of 34 in Kitgum at endline. Even more concerning, quintuple-plus-581G sextuple haplotypes were detected in 1 of 8 isolates in Jinja and 2 of 27 isolates in Kitgum.
These genotypes matter because they sit beyond the classic quintuple resistance pattern. I164L in Pfdhfr and A581G in Pfdhps have been linked to more advanced antifolate resistance, and their appearance in this cohort suggests the local parasite population is not static. Rather than holding at a stable resistance plateau, it is acquiring additional molecular steps that make the SP backbone even less reliable as a preventive strategy.
For clinicians working with children who have sickle cell anaemia, that is not an abstract molecular detail. Chemoprevention only helps if the parasite remains drug-susceptible enough for the regimen to suppress blood-stage infection before clinical malaria takes hold. Once sextuple mutant parasites enter the field, the margin for meaningful protection becomes thinner.
Most infections were monoclonal, but low complexity did not mean low risk
Complexity of infection was mostly low. Of the 67 samples in which COI was estimated, 51 were monoclonal, representing 76.1% of infections. That pattern suggests many children were carrying a single dominant parasite strain at the time of sampling rather than multiple co-infecting clones.
Low complexity of infection does not soften the resistance signal. In fact, monoclonal infection can make the molecular picture easier to interpret because the detected haplotype more directly reflects the infecting strain. In a setting with widespread resistance, a monoclonal infection dominated by a quintuple or sextuple mutant is a clear readout of the selective environment. It also means the parasites surviving in these children are not necessarily being buffered by mixed-strain competition; the resistant strain is simply prevailing on its own.
SP looks increasingly mismatched to the resistance environment
Monthly SP remains the standard malaria chemoprevention regimen in Uganda, but this analysis puts that practice under pressure. When the great majority of isolates already carry the quintuple mutant, and when higher-level markers such as I164L and A581G are appearing, continued reliance on SP becomes biologically difficult to defend for long-term prevention in children with sickle cell anaemia.
The trial context makes the concern even sharper because the molecular substudy was nested inside a randomized comparison of monthly SP with weekly dihydroartemisinin-piperaquine (DP). The article does not provide efficacy outcomes here, but the resistance profile itself points in one direction: a drug can only prevent malaria consistently if the local parasite population remains vulnerable enough for the regimen to retain activity. In East Africa, where antifolate resistance is widespread, the molecular barrier to SP performance is already high.
The burden falls heaviest on a population that can least afford breakthrough malaria. Children with sickle cell anaemia are already at increased clinical risk from infection, anemia, and hospitalization. A chemoprevention regimen that is increasingly mismatched to the parasite population raises the likelihood that febrile episodes will continue despite prophylaxis, forcing clinicians and families to rely on treatment after infection has already taken hold.
Alternative prophylaxis needs formal evaluation
The investigators’ conclusion is supported by the molecular data rather than inflated by speculation. The combination of entrenched quintuple resistance, the emergence of sextuple haplotypes, and the detection of I164L and A581G provides a coherent argument that SP may no longer be the best preventive option for children with sickle cell anaemia in these settings.
What should follow is not guesswork but comparative evaluation of alternative regimens in the same high-risk population. The CHEMCHA framework already placed SP alongside weekly DP, and that kind of direct comparison is the right model for deciding how malaria prevention should be delivered in children with sickle cell anaemia in Uganda. Future policy will need to account for resistance markers as well as clinical outcomes, because molecular surveillance is now showing how far the parasite has moved beyond the older antifolate combination.